$ALMS News

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow

Alumis to Participate in Upcoming September Investor Conferences

Is Alumis (ALMS) Overvalued After Its 121% One Year Return?

Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy

Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?

Guggenheim Downgrades Alumis to Neutral

Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints

Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37

Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25

Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29

HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It

Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis Phase 2b lupus trial misses primary and secondary endpoints

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript